You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大和降中生製藥(01177.HK)評級至「跑贏大市」 目標價下調至3.2元
阿思達克 09-25 11:06
大和發表研究報告指,中生製藥(01177.HK)上半年總收入按年升0.5%至153億元人民幣,當中創新藥收入增10.9%至39億元人民幣,約佔總收入的25%。期內,經調整淨利潤按年增1.2%至15億元人民幣。在全國醫藥領域腐敗問題集中整治工作的狀態下,管理層對今年收入的最新指引更加審慎,目標是錄得「正增長」,而非之前的「個位數增長」指引。 該行預期,在反腐敗整治工作期間,公司的新產品銷售增長將會放緩,分別下調其今年下半年及明年的收入預測5%及1%,又將2023至25年的每股盈測下調9至11%。該行將集團評級由「買入」降至「跑贏大市」,目標價由4.3元下調至3.2元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account